Innovative Pilot Studies of Novel Mechanism of Action Compounds for Treating Psychiatric Disorders (U01) | Apply Online

Opportunity Summary:

The grant opportunity titled "Innovative Pilot Studies of Novel Mechanism of Action Compounds for Treating Psychiatric Disorders (U01)" (Funding Opportunity Number PAR-11-316) is a National Institutes of Health (NIH) cooperative agreement designed to speed up early clinical testing of promising new medications for mental disorders. The focus is on compounds that are "IND-ready," meaning the key preclinical and regulatory groundwork has been completed so that the drug can move into human studies under an Investigational New Drug application. Rather than funding broad discovery research, this program is aimed at experimental medicine style clinical studies that generate clear, decision-driving evidence about whether a new treatment approach is worth advancing into larger and more expensive trials.

A central goal of the FOA is to push forward medications that work through genuinely novel mechanisms of action, including potentially innovative combination approaches, and to do so using rigorous pharmacology-driven methods. The NIH is looking for projects that can quickly answer the kinds of questions that typically slow drug development: does the compound engage the intended biological target in humans, does it produce the expected pharmacological effects, is it safe and tolerable at doses that are likely to be therapeutically relevant, and do early signals justify moving toward efficacy testing in patients. In other words, these studies are intended to reduce uncertainty (de-risk development) so that the most promising candidates can attract follow-on private investment and proceed toward later-stage clinical development and eventual commercialization.

The FOA supports two main types of early phase clinical work. First-in-human (FIH) pharmacology studies are intended to be the initial step of testing a novel compound in people. These studies are expected to measure target engagement and downstream pharmacological effects, along with standard clinical safety and tolerability outcomes. The emphasis is not just on whether participants feel better, but on whether the drug is doing what it is supposed to do biologically, in a way that can guide dosing and trial design. The idea is to build a credible evidence base that can feed directly into proof-of-concept or early efficacy trials in patient populations.

Proof-of-concept (POC) studies, as described in the announcement, are meant to take the next step by evaluating novel compounds in a way that remains tightly anchored to pharmacology and mechanism. These POC projects should use dosing strategies informed by pharmacological data rather than guesswork, and they should again include direct assessment of target engagement. In addition, they are expected to examine how the compound affects clinically relevant physiological systems (for example, measurable biological or functional systems tied to psychiatric symptoms) as well as clinical indicators that suggest whether the intervention is having the desired therapeutic impact. The program is structured to prioritize studies that can produce interpretable mechanistic and translational results quickly, so that developers can make a go/no-go decision without waiting for long, expensive trials that may fail for unclear reasons.

Because this is a U01 cooperative agreement, applicants should expect substantial NIH involvement compared with a traditional investigator-initiated research grant. Cooperative agreements typically mean the NIH program staff will have an active partnership role in shaping milestones, monitoring progress, and ensuring the study stays aligned with program goals. This structure fits the FOA's purpose of accelerating development and producing practical outputs that can support the next stage of clinical testing.

The eligible applicant pool is broad and includes many U.S.-based organizations, such as public and private institutions of higher education, state and local governments, tribal governments and tribal organizations, special district governments, independent school districts, public housing authorities/Indian housing authorities, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), small businesses, and for-profit entities other than small businesses. The announcement explicitly includes eligibility for a range of mission-driven institution types, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), and faith-based or community-based organizations, along with eligible federal agencies and U.S. territories or possessions. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible; however, "foreign components" as defined under NIH policy may be allowed, which generally means a discrete, justified part of the work can take place outside the U.S. under NIH rules. The FOA also notes that there is no cost sharing or matching requirement.

A notable feature of the program is its strong encouragement of partnerships between academia and industry. This reflects the practical reality that IND-ready compounds are often owned, licensed, or developed with commercial partners, and that moving from early human studies into later development usually requires capabilities and funding beyond what academic teams can provide alone. The NIH is signaling that collaborative proposals that pair academic clinical and mechanistic expertise with industry drug development resources, manufacturing, regulatory experience, and longer-term commercialization plans are especially aligned with the intent of the program.

Administratively, the opportunity falls under the Health activity category and is associated with CFDA number 93.242 (Mental Health Research Grants). It was posted August 18, 2011, created November 7, 2011, and the listing indicates an original closing date of September 7, 2014, with a current closing date shown as January 7, 2012, and an archive date of February 7, 2012 (which suggests this specific listing is now closed and archived). The full announcement was available through the NIH grants guide at the provided link (http://grants.nih.gov/grants/guide/pa-files/PAR-11-316.html). For access or technical linking problems, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.

Overall, this FOA is best understood as an NIH effort to bridge a common gap in psychiatric drug development: getting from a scientifically compelling target and an IND-ready compound to the kind of early human evidence that can justify and guide larger trials. By funding carefully designed FIH and POC studies that emphasize target engagement, mechanism-based outcomes, and practical decision-making data, the program aims to increase the odds that innovative treatments for psychiatric disorders can move efficiently from the lab into real-world clinical development.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Exploratory Grant Program in Disease Modification and Prevention in the Epilepsies (P20)

Previous opportunity: 2011 Pacific Northwest Preservation Field School

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 11 316

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 11 316) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 316", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.